These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 25185930)

  • 41. Population Pharmacokinetics of Amikacin Administered Once Daily in Patients with Different Renal Functions.
    Aréchiga-Alvarado NA; Medellín-Garibay SE; Milán-Segovia RDC; Ortiz-Álvarez A; Magaña-Aquino M; Romano-Moreno S
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32041715
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Standard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentrations.
    Roger C; Nucci B; Molinari N; Bastide S; Saissi G; Pradel G; Barbar S; Aubert C; Lloret S; Elotmani L; Polge A; Lefrant JY; Roberts JA; Muller L
    Int J Antimicrob Agents; 2015 Jul; 46(1):21-7. PubMed ID: 25857948
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Ampicillin in Neonates with Hypoxemic-Ischemic Encephalopathy in the Setting of Controlled Hypothermia.
    Cies JJ; Fugarolas KN; Moore WS; Mason RW; Menkiti OR
    Pharmacotherapy; 2017 Apr; 37(4):456-463. PubMed ID: 28226400
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluating renal function and age as predictors of amikacin clearance in neonates: model-based analysis and optimal dosing strategies.
    Illamola SM; Colom H; van Hasselt JG
    Br J Clin Pharmacol; 2016 Sep; 82(3):793-805. PubMed ID: 27198625
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Quantification and Explanation of the Variability of First-Dose Amikacin Concentrations in Critically Ill Patients Admitted to the Emergency Department: A Population Pharmacokinetic Analysis.
    De Winter S; van Hest R; Dreesen E; Annaert P; Wauters J; Meersseman W; Van den Eede N; Desmet S; Verelst S; Vanbrabant P; Peetermans W; Spriet I
    Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):653-663. PubMed ID: 34297338
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: pharmacokinetics and associated outcomes.
    Bacopoulou F; Markantonis SL; Pavlou E; Adamidou M
    J Crit Care; 2003 Jun; 18(2):107-13. PubMed ID: 12800120
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Amikacin Pharmacokinetic-Pharmacodynamic Analysis in Pediatric Cancer Patients.
    Alhadab AA; Ahmed MA; Brundage RC
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29358293
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Population and Developmental Pharmacokinetic Analysis To Evaluate and Optimize Cefotaxime Dosing Regimen in Neonates and Young Infants.
    Leroux S; Roué JM; Gouyon JB; Biran V; Zheng H; Zhao W; Jacqz-Aigrain E
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6626-6634. PubMed ID: 27572399
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Amikacin Dosing for MDR Tuberculosis: A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis Treatment.
    Sturkenboom MGG; Simbar N; Akkerman OW; Ghimire S; Bolhuis MS; Alffenaar JC
    Clin Infect Dis; 2018 Nov; 67(suppl_3):S303-S307. PubMed ID: 30496466
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target?
    Padari H; Oselin K; Tasa T; Metsvaht T; Lõivukene K; Lutsar I
    BMC Pediatr; 2016 Dec; 16(1):206. PubMed ID: 27931193
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Population pharmacokinetics and dosing simulations of cefuroxime in critically ill patients: non-standard dosing approaches are required to achieve therapeutic exposures.
    Carlier M; Noë M; Roberts JA; Stove V; Verstraete AG; Lipman J; De Waele JJ
    J Antimicrob Chemother; 2014 Oct; 69(10):2797-803. PubMed ID: 24917580
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Amikacin nomogram for treatment of adult cystic fibrosis exacerbations based on an external evaluation of a population pharmacokinetic model.
    Thirion DJG; Pasche V; Matouk E; Marsot A
    Pediatr Pulmonol; 2020 May; 55(5):1154-1160. PubMed ID: 32119197
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A prospective study evaluating tobramycin pharmacokinetics and optimal once daily dosing in burn patients.
    Lee C; Walker SAN; Walker SE; Seto W; Simor A; Jeschke M
    Burns; 2017 Dec; 43(8):1766-1774. PubMed ID: 28647460
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity.
    Gálvez R; Luengo C; Cornejo R; Kosche J; Romero C; Tobar E; Illanes V; Llanos O; Castro J
    Int J Antimicrob Agents; 2011 Aug; 38(2):146-51. PubMed ID: 21612894
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with Monte Carlo simulations.
    Ramon-Lopez A; Allen JM; Thomson AH; Dheansa BS; James SE; Hanlon GW; Stewart B; Davies JG
    J Antimicrob Chemother; 2015 Mar; 70(3):882-90. PubMed ID: 25362574
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [In vivo pharmacokinetic of amikacin and its pharmacodynamic in combination with cefepime, cefpirome and meropenem in an in vitro/ex vivo micropig model].
    Elkhaïli H; Pompei D; Peter JD; Linger L; Salmon J; Levêque D; Niedergang S; Salmon Y; Thierry RC; Monteil H; Jehl F
    Pathol Biol (Paris); 1997 May; 45(5):347-56. PubMed ID: 9296083
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Assessment of pharmacokinetic parameters of amikacin in a group of neutropenic patients in onco-hematology].
    Pivot-Dumarest C; Deweerdt C; Troncy J; Sorensen P; Roux D; Maire P
    Pathol Biol (Paris); 1996 Apr; 44(4):299-305. PubMed ID: 8763595
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and Safety of High Vs Standard Daptomycin Doses Examined in Chinese Patients With Severe Burn Injuries by Pharmacokinetic Evaluation.
    Huang Y; Lv G; Hu L; Wu Y; Guo N; Zhu Y; Ding L; Li Q; Liu S; Yang Y; Shao H
    J Burn Care Res; 2020 May; 41(3):705-713. PubMed ID: 32006005
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti-staphylococcal activity resulting from epithelial lining fluid (ELF) concentrations of amikacin inhale administered via the pulmonary drug delivery system.
    Ghazi IM; Grupper M; Nicolau DP
    Ann Clin Microbiol Antimicrob; 2017 Jan; 16(1):2. PubMed ID: 28095918
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Amikacin Pharmacokinetics To Optimize Dosing in Neonates with Perinatal Asphyxia Treated with Hypothermia.
    Cristea S; Smits A; Kulo A; Knibbe CAJ; van Weissenbruch M; Krekels EHJ; Allegaert K
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.